Over the course of the past year or so, the healthcare sector has become one of the hottest sectors to invest in and the situation has continued up until now. For instance, in the past three months alone, Health Care Select Sector SPDR Fund has gone up by almost 100%, and hence, it could be the right time for investors to start looking into healthcare stocks. Here is a look at three healthcare stocks that ought to be on the watch lists of investors at this point.
1. Danaher (NYSE:DHR)
One of the healthcare stocks to have emerged as a major mover this year so far is that of Danaher Business System. It has managed to clock gains of around 50% in 2021 so far and on top of that, the management has projected that adjusted income for the financial year is going to rise by as much as 20%.
The company has a decentralized approach and at this point, it is in control of as many as 20 different operating companies involved in different aspects of its science-based business model. At this point, Danaher is well placed to take advantage of the new shift towards scientific research, and investors could do well to keep an eye on the stock this month.
2. Veeva Systems (NYSE:VEEV)
Veeva Systems has emerged as an interesting disruptor in the healthcare industry considering the fact that in essence it is a tech company and offers cloud-based solutions. However, the company has managed to concentrate solely on the healthcare space and has roped in some massive clients.
Some of Veeva Systems’ clients include such names as Moderna, Novartis, Bayer, Biogen, and AstraZeneca among others. The SaaS or software as a service industry is growing at a remarkable pace and is expected to be worth as much as $307 billion by the time 2026 comes along. In its most recent quarterly financial results, the company announced that its revenues jumped 29% year on year and that is another indication that it is a stock that could be added to the watch lists.
3. Editas Medicine (NASDAQ:EDIT)
Last but certainly not least, it is the Editas Medicine stock that investors could consider looking into this month. The company is involved in the gene-editing space, which is regarded as an industry that is all set to grow explosively in the coming years.
Last month the company was in the news after it announced that it came up with a new gene-editing technology named SLEEK. Although it has no revenue at this point, the stock has performed strongly and is up by 60% over the past six months. Investors are betting on the future.